地西他滨联合伊匹木单抗治疗晚期髓系疾病的应答与耐药机制
研究基于ETCTN/CTEP 10026试验,对48例受试者中18例的304961个骨髓浸润细胞进行转录组分析,发现应答与基线T细胞/AML细胞比值高强相关,临床应答主要由地西他滨诱导的细胞减灭驱动,伊匹木单抗暴露后才出现免疫激活证据。
要点
- 应答与基线T细胞与AML细胞比值高强相关
- 临床应答主要由地西他滨诱导的细胞减灭驱动
- 伊匹木单抗暴露后出现免疫激活并改变CD4+ T细胞基因表达
核心结论
- 地西他滨联合伊匹木单抗的活性受白血病细胞微环境生态位内细胞表达状态影响,白血病祖细胞清除不充分亟需开发靶向这些细胞群的新方法以实现持久应答。
研究设计与样本
- 基于ETCTN/CTEP 10026研究,对48例受试者中18例的304961个骨髓浸润细胞进行整合转录组分析。
主要发现
- 应答与基线T细胞与AML细胞比值高强相关。
- 临床应答主要由地西他滨诱导的细胞减灭驱动。
- 伊匹木单抗暴露后才出现免疫激活证据,其改变CD4+ T细胞基因表达,与T细胞持续分化和骨髓浸润调节性T细胞频率增加一致。
- 移植后样本中复发可归因于祖细胞群中恶性克隆清除不充分。
- 伊匹木单抗单药持久缓解患者的白血病皮肤样本转录组显示抗原经验组织驻留记忆T细胞浸润增加及CTLA-4和FOXP3表达更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML) after initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy. Recently, the ETCTN/CTEP 10026 study tested the combination of the DNA methyltransferase inhibitor decitabine together with the immune checkpoint inhibitor ipilimumab for AML/myelodysplastic syndrome (MDS) either after allogeneic hematopoietic stem cell transplantation (HSCT) or in the HSCT-naïve setting. Integrative transcriptome-based analysis of 304 961 individual marrow-infiltrating cells for 18 of 48 subjects treated on study revealed the strong association of response with a high baseline ratio of T to AML cells. Clinical responses were predominantly driven by decitabine-induced cytoreduction. Evidence of immune activation was only apparent after ipilimumab exposure, which altered CD4+ T-cell gene expression, in line with ongoing T-cell differentiation and increased frequency of marrow-infiltrating regulatory T cells. For post-HSCT samples, relapse could be attributed to insufficient clearing of malignant clones in progenitor cell populations. In contrast to AML/MDS bone marrow, the transcriptomes of leukemia cutis samples from patients with durable remission after ipilimumab monotherapy showed evidence of increased infiltration with antigen-experienced resident memory T cells and higher expression of CTLA-4 and FOXP3. Altogether, activity of combined decitabine and ipilimumab is impacted by cellular expression states within the microenvironmental niche of leukemic cells. The inadequate elimination of leukemic progenitors mandates urgent development of novel approaches for targeting these cell populations to generate long-lasting responses. This trial was registered at www.clinicaltrials.gov as #NCT02890329.
引用
- Penter L, Liu Y, Wolff JO, et al. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023. PMID: 36706355. doi:10.1182/blood.2022018246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。